Abstract
Verastem will report its next quarterly results on November 5, 2026, Post-Mkt; this preview outlines consensus projections for revenue, margins, GAAP and adjusted profitability, and synthesizes the key near-term business drivers and analyst expectations into a comprehensive, numbers-first review.
Market Forecast
Consensus points to revenue of 26.08 million US dollars for the current quarter, reflecting an estimated year-over-year increase of 360.80%, with adjusted EPS projected at -0.46 and an expected year-over-year improvement of 27.80%. EBIT is forecast at -48.14 million US dollars with a year-over-year change of -9.29%; forecasts for gross margin or net margin are not provided, and are therefore omitted.
The main commercial franchise is expected to carry forward its strong unit economics, supported by last quarter’s 90.61% gross margin and sustained uptake dynamics seen in product revenue. The most promising revenue-contributing segment remains the commercial products line, which generated 25.08 million US dollars last quarter against company-wide revenue growth of 1,775.43% year over year, reinforcing the momentum that consensus expects to continue into this quarter.
Last Quarter Review
In the prior quarter, Verastem delivered revenue of 40.08 million US dollars, a gross profit margin of 90.61%, a GAAP net loss attributable to shareholders of 34.67 million US dollars with a net profit margin of -86.51%, and adjusted EPS of -0.35, representing a 10.26% year-over-year improvement; total revenue grew 1,775.43% year over year.
One noteworthy highlight was the sizable revenue outperformance versus street estimates, as revenue exceeded expectations by 16.98 million US dollars while adjusted EPS beat by 0.08 and the net profit improved quarter-on-quarter by 5.24%. From a business mix perspective, commercial products generated 25.08 million US dollars and the sale of a COPIKTRA license and related assets contributed 15.00 million US dollars, collectively underpinning the outsized year-over-year revenue expansion.
Current Quarter Outlook
Main commercial franchise
The core commercial franchise remains the centerpiece for near-term financial performance. The previous quarter’s 90.61% gross margin demonstrated a favorable revenue-cost relationship that should keep overall contribution margins resilient even as operating expenses scale to support launch execution. Product revenue of 25.08 million US dollars last quarter provides a strong baseline, and consensus implies a normalization in quarterly revenue toward 26.08 million US dollars this quarter, as one-time contributions from asset transactions normalize and the recurring product run-rate drives the bulk of sales.
Executionally, the variables to watch are patient starts, earlier-line prescribing behavior, and refills that cumulatively shape quarterly revenue recognition. Analyst commentary highlights that the commercial strategy emphasizing depth, earlier prescribing, and refill durability appears to be taking hold, which aligns with a sustained revenue cadence rather than one-off spikes. With a high gross margin, each incremental dollar of product revenue has an outsized impact on gross profit dollars, so even moderate sequential gains can materially influence quarterly EBIT, while any disciplined approach to commercial spending can accelerate operating leverage.
Given last quarter’s operating expense intensity and the reported operating loss cadence, the margin lens for this quarter rests on balancing top-line consistency with operating expense discipline. EBIT is forecast at -48.14 million US dollars, and while this implies a year-over-year deterioration of 9.29%, investors will likely interpret the print through the lens of revenue quality, prescription trends, and evidence of improving unit economics that can bridge toward medium-term operating breakeven. The company’s own pre-quarter trajectory, including a clear product contribution and a previously demonstrated ability to beat revenue estimates, keeps the focus on whether current-quarter revenue can track the 26.08 million US dollars consensus while preserving the gross margin profile.
Pipeline program VS-7375 (KRAS G12D)
The VS-7375 program is poised to remain a central investment narrative for the company’s multi-quarter outlook. This quarter’s framework integrates early clinical signals reported during the period, including confirmed response rates in pancreatic and lung settings and a manageable safety profile at clinically explored doses. These data points matter for the near-term equity story because they contextualize how the pipeline could complement the commercial franchise over the mid-horizon and inform capital allocation. The company’s financing update during the period—an underwritten equity offering sized to deliver approximately 250 million US dollars in gross proceeds—reinforces liquidity to execute on development plans, while investors will be attentive to how the spending curve maps against projected readouts and study expansions.
While near-term financials are driven by the commercial franchise, pipeline momentum can indirectly influence stock performance by shaping forward revenue expectations, partnership optionality, and valuation. Analysts have emphasized that the program’s emerging efficacy profile could support a differentiated positioning, albeit with the standard caveats around cross-trial comparisons and data immaturity. Within this quarter, investors will be monitoring any commentary that refines timelines for subsequent data disclosures, dose optimization plans, and possible regulatory interactions, as these markers can materially shift medium-term expectations even if they do not directly affect the current quarter’s P&L.
Quarter-specific stock price drivers
Three elements appear most likely to influence the shares around the print. First, revenue quality and sustainability are central: consensus expects 26.08 million US dollars, and any evidence of durable patient refills and earlier-line adoption will bolster confidence in the commercial trajectory, especially with the tailwind from last quarter’s 90.61% gross margin. Second, the expense line will attract scrutiny; last quarter’s operating expense levels and a GAAP net margin of -86.51% indicate that cost discipline and prioritization will be important signals for the path toward operating leverage. A visible alignment between revenue growth and operating expense pacing would be interpreted constructively.
Third, corporate developments during the period—including leadership changes and strengthened capitalization—frame the strategic capacity to execute. The appointment of a new chief executive officer effective January 1 and the completed equity financing provide continuity and the resources to advance both the commercial and development agendas. The market has already registered this as a constructive development, and commentary on how leadership plans to prioritize capital across commercialization and development milestones could influence post-print sentiment. Altogether, the stock’s near-term setup leans on delivering consensus-like revenue, demonstrating ongoing gross margin resilience, evidencing expense control, and sharpening the roadmap for pipeline catalysts.
Analyst Opinions
The collected broker and institutional commentary from January 1 to October 29 indicates a decisively bullish tilt, with a tally of at least eight bullish views versus zero bearish views, reflecting a 100% bullish majority in the observed period. Several well-known institutions have reiterated or raised their constructive stances and price targets while pointing to both the commercial franchise and the pipeline as key supports for the equity narrative. RBC Capital Markets has maintained and later raised its price target, citing that the shares do not fully reflect the potential of the commercial franchise and the pipeline; its view emphasizes that a refined launch strategy aimed at increasing depth of use, earlier prescribing, and durability appears to be working and could set the franchise on a trajectory toward profitability by year end. H.C. Wainwright has repeatedly reiterated a Buy rating with a double-digit price target, highlighting durable efficacy signals within the company’s clinical programs and the potential for label expansion to broaden the revenue base over time.
B. Riley has increased its price target while maintaining a Buy rating, indicating confidence in the uptick of commercial revenue and the optionality embedded in the pipeline. Mizuho has maintained an Outperform rating and reiterated that the valuation remains attractive relative to the company’s forward growth profile, anchoring the argument in the combination of recurring product revenue and developing late-preclinical/clinical assets. Wolfe Research has initiated at Outperform during the period, adding another constructive voice to the chorus of positive views that underpin current sentiment.
The bullish consensus coalesces around three core arguments. First, the commercial franchise is generating meaningful revenue, as evidenced by the 25.08 million US dollars in product sales last quarter, and the gross margin of 90.61% positions the business to translate incremental revenue into strong gross profit dollars. Second, consensus expects revenue of 26.08 million US dollars this quarter with a year-over-year increase of 360.80% and adjusted EPS at -0.46 with year-over-year improvement of 27.80%, which, if achieved, would validate that the revenue base is not only growing but also contributing to incremental loss moderation. Third, the pipeline program VS-7375 has delivered early response signals that, while preliminary, support continued investment and could introduce longer-horizon value creation pathways; the company’s capital raise during the period further reduces financing overhang and supports this investment case.
Analysts also acknowledge near-term sensitivities. Many note that EBIT is forecast at -48.14 million US dollars with a year-over-year change of -9.29%, indicating that operating losses will persist in the immediate term and raising the importance of matching commercial growth with expense discipline. Within this framework, the most common positive scenario presented by the bullish cohort ties to delivering a revenue print at or above 26.08 million US dollars alongside stable or better-than-expected margin dynamics, plus any incremental signal of adoption depth or refill durability. A secondary positive scenario relates to pipeline updates: clarity on timelines, dose strategy, or expanded study cohorts can incrementally de-risk the program’s trajectory and sustain valuation support.
In summary, the prevailing institutional view is that the current quarter provides a practical checkpoint on commercialization consistency and expense management, with the potential to support shares if revenue, margin, and operating execution align with consensus. The bullish majority places substantial weight on the combination of a high-margin commercial base and credible, early-stage pipeline progress, with price targets clustered in the low-to-high teens that reflect the expectation of continued revenue growth and ongoing clinical de-risking over the coming quarters.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments